buspirone and SSRIs are both non-controlled medications for anxiety, but they work differently and fit different patients. SSRIs are first-line for most anxiety disorders. Buspirone is a reasonable monotherapy for some patients with generalized anxiety, particularly those who can't tolerate SSRI sexual side effects or who specifically want a non-serotonergic option. Its most common role in practice is augmentation: added to an SSRI for partial responders.
The short version
For generalized anxiety as monotherapy, SSRIs have stronger evidence and are usually first-line. Buspirone has its niche: patients with prominent SSRI sexual side effects, patients who want to avoid the SSRI class for personal reasons, and patients who have responded partially to an SSRI and need augmentation rather than a different first agent. For panic disorder, OCD, social anxiety, and PTSD, buspirone is generally not effective and SSRIs are clearly preferred. See the buspirone reference for the longer drug profile and the how CBT and SSRIs work reference for the SSRI class context.
How they differ
Mechanism
SSRIs block the serotonin transporter, increasing serotonin in the synapse. Over weeks, this produces broad receptor adaptation in anxiety circuitry. PsychiatryRx has an animated guide to the SSRI side of this (it doesn't cover buspirone).
Buspirone is a partial agonist at the 5-HT1A serotonin receptor and has weak dopamine antagonist activity. Its mechanism is narrower than SSRIs', which is part of why it works for some conditions and not others. The MedlinePlus buspirone page is a useful consumer reference.
Indications
SSRIs are FDA-approved across major depressive disorder, generalized anxiety, panic disorder, OCD, social anxiety, and PTSD (the exact list varies by molecule).
Buspirone is FDA-approved only for generalized anxiety disorder. It doesn't have meaningful evidence in panic disorder, OCD, social anxiety, or PTSD.
Timeline
Both classes require weeks to produce therapeutic effect on anxiety. Buspirone is sometimes described as slower than SSRIs; in practice the timelines overlap, with two to four weeks before noticeable change at adequate dose.
Side effects
SSRIs commonly produce nausea in the first weeks, sexual side effects that may persist, sleep changes, and a transient anxiety increase early in treatment. Modest weight gain over months is possible.
Buspirone commonly produces dizziness (often dose-related), headache, lightheadedness, and nausea. It doesn't produce sexual side effects, weight gain, or sedation in most patients.
Dependence and withdrawal
Neither produces addiction. SSRIs produce a discontinuation syndrome that requires a gradual taper. Buspirone doesn't produce a discontinuation syndrome and can be stopped without a taper.
Dosing
SSRIs are typically once daily. Buspirone is typically three times daily, which is a real-world adherence problem for many patients. The total daily dose for generalized anxiety is usually 30 to 60 mg, divided into three doses of 10 to 20 mg each. Doses below 30 mg daily are usually inadequate, which is part of why patients sometimes conclude the medication doesn't work.
When to choose an SSRI
- First-line treatment for most anxiety disorders
- Panic disorder, OCD, social anxiety, or PTSD as the primary presentation
- Patient with prominent depressive symptoms alongside anxiety
- Patient where once-daily dosing matters for adherence
When to choose buspirone
- Patient with generalized anxiety where prior SSRI sexual side effects were limiting
- Patient who specifically wants to avoid the SSRI class
- Patient on an SSRI with partial response, where buspirone augmentation is being considered
- Patient where the absence of sedation and weight gain matters
When both are reasonable
- Mild-to-moderate generalized anxiety in a patient with no strong preference
- Patient with co-occurring anxiety and depression, where adding buspirone to an SSRI is being considered
What if neither works
Sequential trials within each class, dose optimization, and the addition of CBT are the usual next steps. SNRIs such as venlafaxine and duloxetine are also reasonable alternatives. The NIMH anxiety disorders overview describes the broader treatment landscape.